The COVID-19 pandemic has severely impacted cancer diagnosis rates, with a study published in Lancet Oncology revealing that more than 55,000 expected cancer cases were missed in the first nine months of 2020 across seven countries, including Australia and the UK. In Australia, diagnostic rates for melanoma and rectal cancers were particularly affected, with declines of 11% and 10% respectively. Oncologists are now observing a surge in late-stage diagnoses, particularly bowel cancer, which require more invasive treatments. Dr. Cameron McLaren emphasized that many patients are presenting at stage 3, leading to concerns about higher recurrence rates. Professor Declan Murphy reported treating patients whose cancers progressed to advanced stages due to missed screenings during the pandemic. For instance, one patient’s prostate-specific antigen readings soared from 4.2 to 60 after delays in testing. Personal accounts, such as that of Cheryl Priest, illustrate the devastating effects of these delays, as she underwent major surgeries and chemotherapy for pancreatic and lung cancer after missing routine check-ups. Experts stress the importance of ongoing surveillance and encourage individuals to seek medical advice for any health concerns.